favoriteGLP-1 + Co-Condition

GLP-1s and Heart Disease

Semaglutide is now FDA-approved to reduce major cardiovascular events in adults with obesity and established heart disease — even without diabetes. Here is what the SELECT trial showed, what the mechanism appears to be, and what tirzepatide still has to prove.

The short answer

GLP-1 medications now have direct cardiovascular evidence in patients with established heart disease. The landmark SELECT trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by about 20% in adults with overweight or obesity and pre-existing cardiovascular disease — without requiring a diabetes diagnosis. Wegovy carries an FDA cardiovascular indication for this group as of 2024. Tirzepatide's outcomes trial (SURPASS-CVOT) has not reported published outcomes yet as of early 2026.

What the research shows

SELECT was the trial that changed the conversation. Published in NEJM in late 2023, it enrolled 17,604 adults aged 45 and older with BMI of 27 or higher and established cardiovascular disease — prior heart attack, prior stroke, or peripheral artery disease — but without diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo and followed for a mean of about 40 months. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (MACE).

Semaglutide reduced MACE by 20% — a hazard ratio of 0.80, statistically significant. Individual components also trended in the same direction, with cardiovascular death reduced by 15% and non-fatal MI by 28%. Weight loss in the trial was modest by SURMOUNT-1 standards (about 9–10% mean), and importantly, the cardiovascular benefit appeared early — within the first few months — before substantial weight loss had occurred. That timing argues for direct vascular effects, not just downstream consequences of weight loss.

The earlier T2D outcomes trials had already pointed in this direction. SUSTAIN-6 (semaglutide in T2D) showed a 26% MACE reduction. LEADER (liraglutide in T2D) showed 13%. REWIND (dulaglutide) showed 12%. The pattern across the long-acting GLP-1 class has been consistent enough that the ADA recommends GLP-1 receptor agonists for any T2D patient with established CV disease, independent of A1c. SELECT extended that logic to the non-diabetic obese population.

Mechanism is still being unpacked, but the working hypothesis combines several effects. GLP-1 receptors are present on vascular endothelium and atherosclerotic plaques. The drugs reduce inflammation (CRP drops measurably), improve endothelial function, lower systolic blood pressure by 5–8 mmHg, modestly improve lipids, and reduce weight and visceral fat. Some of the protection is plausibly upstream of all of those — direct anti-inflammatory or anti-atherosclerotic action — though the proportion is hard to disentangle.

How it tends to work in practice

The cardiologist's view of a GLP-1 has changed sharply in the last two years. For a patient with established coronary disease, prior MI, or prior stroke who also has BMI 27 or higher, a GLP-1 is now often added alongside statin, aspirin or other antiplatelet, and antihypertensives — not as an alternative to those drugs, but as additive secondary prevention. The expectation isn't necessarily aggressive weight loss; SELECT participants lost less weight than weight-loss-trial averages, and benefit was still substantial.

Blood pressure changes are usually the first cardiac variable to shift. Within 4–8 weeks, many patients see systolic drops of 5–10 mmHg, which can require reductions in antihypertensive doses to avoid lightheadedness. Heart rate tends to rise modestly (3–5 bpm on average) — a known class effect that has not translated into adverse cardiac outcomes in the trials, but is something cardiologists tend to watch.

Heart failure is a more nuanced area. GLP-1s have been studied in heart failure with preserved ejection fraction (HFpEF) with positive results — the STEP-HFpEF trials showed semaglutide improved heart-failure symptoms and exercise capacity in obese HFpEF patients. In heart failure with reduced ejection fraction (HFrEF), the data are less consistent and some earlier liraglutide work suggested possible harm. The current guidance favors caution in HFrEF and clear benefit in HFpEF with obesity.

Key considerations

verified

Wegovy has an FDA cardiovascular indication

Since 2024, Wegovy is approved to reduce MACE in adults with established cardiovascular disease and overweight/obesity, even without diabetes. This is the first non-diabetes obesity drug to carry that label.

speed

Benefit appears early

In SELECT, cardiovascular event curves diverged within months, before major weight loss. That argues for direct vascular effects, not just weight-loss-driven benefit.

medication

Layer on, don't replace

GLP-1s for cardiac protection are additive to statins, antiplatelets, and antihypertensives — not a substitute. Your cardiologist may adjust blood pressure meds within the first few weeks.

Common questions

Common Concerns

Should I take a GLP-1 if I've had a heart attack but no diabetes?expand_more

If you also have BMI of 27 or higher, yes — this is the SELECT population, and Wegovy is FDA-labeled for exactly this scenario. Discuss with both your cardiologist and a prescriber who handles GLP-1s. Insurance pathways under the cardiovascular indication can be more favorable than the obesity-only path.

Does tirzepatide also reduce cardiac events?expand_more

Almost certainly, but the formal outcomes trial — SURPASS-CVOT — has not reported published results as of early 2026. Cardiologists generally treat the cardiovascular benefit as a likely class effect, but tirzepatide does not yet carry an FDA cardiovascular indication.

Will my heart rate go up?expand_more

Modestly, yes. Mean increases of 3–5 bpm are typical and have not translated into adverse outcomes in any of the trials. If you have a baseline arrhythmia or tachycardia, your cardiologist will monitor more closely.

Is a GLP-1 safe with heart failure?expand_more

It depends on the type. In heart failure with preserved ejection fraction (HFpEF) with obesity, the STEP-HFpEF trials showed clear symptomatic benefit. In heart failure with reduced ejection fraction (HFrEF), the data are less consistent and many specialists are more cautious.

Can I stop my statin if I'm on a GLP-1?expand_more

No. The GLP-1 cardiac benefit is additive to statins, not a replacement. SELECT participants were largely on statins, and the 20% MACE reduction was on top of standard medical therapy. Continue all cardiac medications unless your cardiologist tells you otherwise.

Keep exploring

Browse all GLP-1 guides.